Last reviewed · How we verify
Iproclozid (IPROCLOZIDE)
Iproclozid (generic name: IPROCLOZIDE) is a Monoamine Oxidase Inhibitors drug. It is currently in Phase 2 development for Depressive disorder.
Iproclozide works by blocking the enzyme that breaks down certain neurotransmitters in the brain, allowing their levels to increase and improve mood.
Iproclozide is a small molecule Monoamine Oxidase Inhibitors (MAOIs) drug, originally developed by an unknown entity, but currently owned by an unspecified company. It is used to treat depressive disorder, although its commercial status and patent information are unknown. As a MAOI, it works by inhibiting the enzyme monoamine oxidase, which breaks down certain neurotransmitters in the brain, thereby increasing their levels and improving mood. The exact target of iproclozide is unknown, but it is believed to affect the levels of serotonin, norepinephrine, and dopamine. Further information on its pharmacokinetics and safety profile is not available.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IPROCLOZIDE |
|---|---|
| Drug class | Monoamine Oxidase Inhibitors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is a city with many roads (neurotransmitters) that help you feel happy or sad. Iproclozide is like a traffic cop that stops the garbage trucks (monoamine oxidase) from breaking down the roads, so more people (neurotransmitters) can use them, making you feel better.
Approved indications
- Depressive disorder
Common side effects
Drug interactions
- Alpha/Beta Agonists
- Amphetamines
- Indirectly Acting Sympathomimetic Amines
- Selective Serotonin Reuptake Inhibitors
- Serotonin/Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- buspirone
- dextromethorphan
- levodopa
- methyldopa
- mirtazapine
- pethidine
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iproclozid CI brief — competitive landscape report
- Iproclozid updates RSS · CI watch RSS
Frequently asked questions about Iproclozid
What is Iproclozid?
How does Iproclozid work?
What is Iproclozid used for?
What is the generic name of Iproclozid?
What drug class is Iproclozid in?
What development phase is Iproclozid in?
Related
- Drug class: All Monoamine Oxidase Inhibitors drugs
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Depressive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing